172 related articles for article (PubMed ID: 35546653)
21. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
23. Pain and pain medication use in community-dwelling older adults.
Sawyer P; Bodner EV; Ritchie CS; Allman RM
Am J Geriatr Pharmacother; 2006 Dec; 4(4):316-24. PubMed ID: 17296537
[TBL] [Abstract][Full Text] [Related]
24. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
25. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.
Bigal ME; Serrano D; Buse D; Scher A; Stewart WF; Lipton RB
Headache; 2008 Sep; 48(8):1157-68. PubMed ID: 18808500
[TBL] [Abstract][Full Text] [Related]
26. Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications.
Sharpless LK; Kesselheim AS; Orr SL; Darrow J
Neurology; 2023 Sep; 101(10):e989-e1000. PubMed ID: 37438124
[TBL] [Abstract][Full Text] [Related]
27. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
28. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Buse DC; Serrano D; Holland S; Reed ML
Headache; 2013 Sep; 53(8):1300-11. PubMed ID: 23879870
[TBL] [Abstract][Full Text] [Related]
29. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
Cady RK; Schreiber CP; Beach ME; Hart CC
Med Sci Monit; 2005 Sep; 11(9):PI65-9. PubMed ID: 16127373
[TBL] [Abstract][Full Text] [Related]
30. Caffeine in the management of patients with headache.
Lipton RB; Diener HC; Robbins MS; Garas SY; Patel K
J Headache Pain; 2017 Oct; 18(1):107. PubMed ID: 29067618
[TBL] [Abstract][Full Text] [Related]
31. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.
Lipton RB; Munjal S; Buse DC; Alam A; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
Headache; 2019 Sep; 59(8):1310-1323. PubMed ID: 31410844
[TBL] [Abstract][Full Text] [Related]
32. Drugs for the acute treatment of migraine in children and adolescents.
Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010
[TBL] [Abstract][Full Text] [Related]
33. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
Lipton RB; Hutchinson S; Ailani J; Reed ML; Fanning KM; Manack Adams A; Buse DC
Headache; 2019 Nov; 59(10):1762-1772. PubMed ID: 31544244
[TBL] [Abstract][Full Text] [Related]
35. Medication patterns of recurrent headache sufferers: a community study.
Forward SP; McGrath PJ; MacKinnon D; Brown TL; Swann J; Currie EL
Cephalalgia; 1998 Apr; 18(3):146-51. PubMed ID: 9595208
[TBL] [Abstract][Full Text] [Related]
36. Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study.
Dodick DW; Reed ML; Fanning KM; Munjal S; Alam A; Buse DC; Schwedt TJ; Lipton RB
Cephalalgia; 2019 Jun; 39(7):873-882. PubMed ID: 30732460
[TBL] [Abstract][Full Text] [Related]
37. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features.
Lipton RB; Serrano D; Holland S; Fanning KM; Reed ML; Buse DC
Headache; 2013 Jan; 53(1):81-92. PubMed ID: 23078241
[TBL] [Abstract][Full Text] [Related]
38. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.
Bigal ME; Rapoport AM; Sheftell FD; Tepper SJ; Lipton RB
Cephalalgia; 2004 Jun; 24(6):483-90. PubMed ID: 15154858
[TBL] [Abstract][Full Text] [Related]
39. Headache pain model for assessing and comparing the efficacy of over-the-counter analgesic agents.
Schachtel BP; Thoden WR; Konerman JP; Brown A; Chaing DS
Clin Pharmacol Ther; 1991 Sep; 50(3):322-9. PubMed ID: 1914366
[TBL] [Abstract][Full Text] [Related]
40. A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches.
Peck J; Urits I; Zeien J; Hoebee S; Mousa M; Alattar H; Kaye AD; Viswanath O
Curr Pain Headache Rep; 2020 Mar; 24(5):19. PubMed ID: 32200435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
